Möchten Sie immer auf dem neuesten Stand bleiben?

MOVENTIG® APPROVED IN THE EUROPEAN UNION FOR OPIOID-INDUCED CONSTIPATION First in class treatment approved for adult patients with opioid-induced constipation who have had an inadequate response to...

JURY VERDICT FAVOURS ASTRAZENECA IN NEXIUM ANTITRUST LITIGATION AstraZeneca today announced that a jury in the US District Court for the District of Massachusetts returned a verdict in favour of...

NEW DRUG APPLICATION FOR IRESSA ACCEPTED BY US FOOD AND DRUG ADMINISTRATION AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted for filing the New Drug...

AMGEN AND ASTRAZENECA ANNOUNCE POSITIVE RESULTS FROM THIRD AND FINAL PIVOTAL PHASE III STUDY OF BRODALUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Study met all primary endpoints against...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION Publication of Final Terms in relation to the...

DUAKLIR® GENUAIR® approved in the EUROPEAN union FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AstraZeneca today announced that Duaklir® Genuair® (aclidinium bromide/formoterol fumarate 340/12 mcg) has...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION AstraZeneca launches and prices a €750,000,000 7...

·     Late-stage pipeline transformed well ahead of plan through increased R&D productivity, accelerated programmes and targeted business development; 14 potential new medicines in Phase III or...

Publication of Supplemental Prospectus Following a routine technical update in June 2014 of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following...

AMGEN AND ASTRAZENECA ANNOUNCE POSITIVE RESULTS FROM SECOND PIVOTAL PHASE III STUDY OF BRODALUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS Brodalumab meets all primary and all key...